Workflow
Freeline Therapeutics(FRLN) - 2023 Q2 - Quarterly Report

股东批准事项 - 公司2022年度报告和账目获得股东批准,50,975,524票赞成,占比99.74%[4] - 2022年董事薪酬报告获得股东批准,43,604,803票赞成,占比85.38%[4] - Deloitte LLP重新任命为审计师,50,995,962票赞成,占比99.78%[4] 董事重新任命 - Chris Hollowood重新任命为董事,43,635,554票赞成,占比99.62%[4] - Martin Andrews重新任命为董事,50,927,175票赞成,占比99.66%[4] - Jeffrey A. Chodakewitz重新任命为董事,50,662,448票赞成,占比99.13%[4] - Julia P. Gregory重新任命为董事,50,934,698票赞成,占比99.67%[4] - Colin A. Love重新任命为董事,50,936,269票赞成,占比99.67%[4] - Michael J. Parini重新任命为董事,50,930,566票赞成,占比99.67%[4] 新董事任命 - Paul Schneider任命为董事,50,933,251票赞成,占比99.67%[6]